



20 June 2022

Acrux announces commercial agreement with Padagis

Melbourne, Australia; 20 June 2022: Acrux Limited (ASX:ACR) is pleased to announce that it has entered into an exclusive commercialisation agreement with Padagis in the United States for one of the products in the Acrux portfolio.

Padagis is a leading US-based provider of extended topical and other specialty pharmaceutical products with over two hundred products on the market today. Formerly the Rx Pharmaceuticals division of Perrigo, Padagis is now a privately-held organisation with manufacturing operations in the United States and Israel and complimentary distribution and commercialisation capabilities in those markets.

Padagis will be responsible for the commercialisation of the product, including sales, distribution and coordination of manufacturing. Padagis and Acrux will share the profits generated from the sales of the product.

The details of the product and plans for its launch are commercially sensitive and are therefore unable to be revealed at this time. The product is expected to be launched in the United States during the second half of 2022. Further disclosures will be made at the appropriate time.

----- ENDS -----

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director
P: + 61 3 8379 0100
E: michael.kotsanis@acrux.com.au



About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

About Padagis

Padagis is dedicated to improving the well-being of as many patients and consumers as possible by developing, manufacturing and distributing high quality, affordable specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide.

For further information on Padagis, visit <https://padagis.com/>